Biopharma in China

Innovation, Trends and Dealmaking

Inbunden, Engelska, 2024

549 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

This book provides an insider’s overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this.

Produktinformation

Utgivningsdatum2024-04-17
Mått148 x 210 x 14 mm
Vikt333 g
FormatInbunden
SpråkEngelska
Antal sidor155
Upplaga2024
FörlagSpringer Verlag, Singapore
ISBN9789819714704

Tillhör följande kategorier

Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma.Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities.

Chapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril.- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration.- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem.- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class.- Chapter 5: The art of the biopharma deal: The China angle.- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.